STOCK TITAN

MariMed Announces First Quarter 2023 Earnings Date

MariMed Inc. (CSE: MRMD, OTCQX: MRMD), a leading multi-state cannabis operator, will report its Q1 2023 financial results on May 8, 2023, after market close.

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags

Rhea-AI Summary

MariMed Inc. (CSE: MRMD, OTCQX: MRMD), a leading multi-state cannabis operator, will report its Q1 2023 financial results on May 8, 2023, after market close. Management will host a conference call on May 9, 2023, at 8:00 a.m. EST to discuss the financial outcomes. The call will be accessible via a webcast on MariMed’s Investor Relations website, where a playback will also be available. MariMed is dedicated to improving lives through its high-quality cannabis products, utilizing state-licensed facilities and proprietary formulations that underpin its popular brands such as Betty's Eddies and Nature’s Heritage.

Loading...
Loading translation...

Positive

  • Upcoming Q1 2023 financial results report on May 8, 2023, indicating transparency.
  • Management conference call scheduled for May 9, 2023, allowing for direct investor communication.

Negative

  • None.
Argus Session date unavailable
+1.27% session move Open Argus
Details

News Market Reaction – MRMD

The recorded move for MRMD in the trading session of this news was +1.27%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

NORWOOD, Mass., April 11, 2023 (GLOBE NEWSWIRE) -- MariMed Inc. (“MariMed” or the “Company”), (CSE: MRMD), (OTCQX: MRMD), a leading multi-state cannabis operator focused on improving lives every day, today announced it will report its first quarter 2023 financial results on May 8, 2023 after the markets close. Management will host a conference call on May 9, 2023 at 8:00 a.m. EST to discuss financial results.

A webcast will be available and can be accessed via MariMed’s Investor Relations website at MariMed Q123 Earnings Webcast. A playback of the call will be made available on MariMed’s Investor Relations website.

About MariMed
MariMed Inc., a multi-state cannabis operator, is dedicated to improving lives every day through its high-quality products, its actions, and its values. The Company develops, owns, and manages seed to sale state-licensed cannabis facilities, which are models of excellence in horticultural principles, cannabis cultivation, cannabis-infused products, and dispensary operations. MariMed has an experienced management team that has produced consistent growth and success for the Company and its managed business units. Proprietary formulations created by the Company’s technicians are embedded in its top-selling and award-winning products and brands, including Betty's Eddies, Nature’s Heritage, InHouse, Bubby’s Baked, K Fusion, Kalm Fusion, and Vibations: High + Energy. For additional information, visit www.marimedinc.com.

Investor Relations Contact:
Steve West
Vice President, Investor Relations
Email: ir@marimedinc.com
Phone: (781) 277-0007

Company Contact:
Howard Schacter
Chief Communications Officer
Email: hschacter@marimedinc.com
Phone: (781) 277-0007


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will MariMed report its Q1 2023 financial results?

MariMed will report its Q1 2023 financial results on May 8, 2023, after market close.

What time is the MariMed conference call for financial results?

The conference call to discuss MariMed's financial results is scheduled for May 9, 2023, at 8:00 a.m. EST.

Where can I access the MariMed earnings webcast?

The earnings webcast can be accessed via MariMed’s Investor Relations website.

Keep reading